FDA lists 200 cancer targets that could require pediatric trials

In a move to spur development of drugs for pediatric populations and require more studies of pediatric cancers, FDA published Tuesday a list of 200 molecular targets that could trigger a requirement to conduct pediatric clinical studies. The agency can choose to mandate pediatric trials for compounds against a listed target even if the compound has Orphan Drug designation for the pediatric population, or if the adult indication does not occur in children.